Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

February 9, 2024
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared HolzAmgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to talk Amgen’s obesity drug trial results.


 

Share This

Latest Mizuho News

See all news
Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

April 20, 2026
Iran war highlights risks in the chemical supply chain

Iran war highlights risks in the chemical supply chain

April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire

Wall Street jumps to near one-month highs after US-Iran ceasefire

April 8, 2026

Mizuho news from around the globe

 Mizuho Global News
back-to-top-blue